LIQUIDIA TECHNOLOGIES, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-10-26: Study NCT07748000; Company role Lead sponsor; Phase Phase 2; Status Not yet recruiting.
- 2026-09: Study NCT07759804; Company role Lead sponsor; Phase Phase 4; Status Not yet recruiting.
- 2026-07-15: Study NCT07561034; Company role Collaborator; Phase Not applicable; Status Recruiting.
- 2026-04-23: Study NCT07285655; Company role Lead sponsor; Phase Phase 3; Status Recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-10-26 | NCT07748000 A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks | Lead sponsor | Phase 2 | Not yet recruiting | Raynaud's Phenomenon Secondary to Systemic Sclerosis | 75 | 2027-03 |
| 2026-09 | NCT07759804 A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | Lead sponsor | Phase 4 | Not yet recruiting | Pulmonary Arterial Hypertension (PAH) | 20 | 2027-06 |
| 2026-07-15 | NCT07561034 The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease | Collaborator Lead: University of Rochester | Not applicable | Recruiting | Pulmonary Hypertension; Interstitial Lung Disease | 30 | 2027-05-30 |
| 2026-04-23 | NCT07285655 A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD | Lead sponsor | Phase 3 | Recruiting | Pulmonary Hypertension Due to Lung Disease (Disorder) | 344 | 2031-12 |
| 2023-12-28 | NCT06129240 An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH | Lead sponsor | Observational | Recruiting | Pulmonary Hypertension; Interstitial Lung Disease | 80 | 2028-02-08 |
| 2021-08-01 | NCT04691154 A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD | Lead sponsor | Phase 3 | Active not recruiting | Pulmonary Arterial Hypertension; Pulmonary Hypertension Due to Lung Diseases | 28 | 2031-03-31 |
| 2019-11-11 | NCT03884465 Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil | Lead sponsor | Phase 2 | Terminated | Pulmonary Arterial Hypertension | 15 | 2020-12-23 |
| 2019-07-18 | NCT03992755 Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil | Lead sponsor | Phase 3 | Active not recruiting | Primary Pulmonary Hypertension | 92 | 2025-05-31 |
| 2018-01-02 | NCT03399604 Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil | Lead sponsor | Phase 3 | Completed Results posted | Primary Pulmonary Hypertension | 121 | 2019-11-25 |
| 2016-12-05 | NCT02982889 Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations | Lead sponsor | Phase 1 | Completed | Acute Pain | 29 | 2017-04-26 |
| 2010-09 | NCT01224262 A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 | Lead sponsor | Phase 1, Phase 2 | Completed | Influenza | 152 | 2011-12 |